Cyanotech (CYAN) Stock Price, News & Analysis

Company Overview

Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

Key Stats

• Today's Range: $0.37 to $0.39
• 50-Day Range: $2.83 to $3.26
• 52-Week Range: $2.37 to $6.29
• Volume: 1,500 shs
• Average Volume: 3,483 shs
• Market Capitalization: $2.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Cyanotech Stock Analysis - MarketRank™

Cyanotech scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cyanotech.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cyanotech is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cyanotech is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cyanotech has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the outstanding shares of Cyanotech have been sold short.

Short Interest Ratio / Days to Cover

Cyanotech has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyanotech has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyanotech does not currently pay a dividend.

Dividend Growth

Cyanotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the outstanding shares of Cyanotech have been sold short.

Short Interest Ratio / Days to Cover

Cyanotech has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyanotech has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Cyanotech this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cyanotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.10% of the stock of Cyanotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 24.40% of the stock of Cyanotech is held by institutions.

CYAN Stock Analysis - Frequently Asked Questions

How were Cyanotech's earnings last quarter?

Cyanotech Co. (NASDAQ:CYAN) released its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.16) EPS for the quarter. The biotechnology company had revenue of $5.85 million for the quarter. Cyanotech had a negative trailing twelve-month return on equity of 44.71% and a negative net margin of 19.50%.

What other stocks do shareholders of Cyanotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyanotech investors own include AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Allena Pharmaceuticals (ALNA), Clarivate (CCC), Karyopharm Therapeutics (KPTI) and Madrigal Pharmaceuticals (MDGL).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 8/02/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CYAN
• CIK: 768408
• Web: www.cyanotech.com
• Phone: (808) 326-1353
• Fax: 808-329-4533
• Employees: 95
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.27 million
• Net Margins: -19.50%
• Pretax Margin: -19.48%
• Return on Equity: -44.71%
• Return on Assets: -19.12%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 1.06
• Quick Ratio: 0.28

Sales & Book Value

• Annual Sales: $23.07 million
• Price / Sales: 0.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.33 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 7,160,000
• Free Float: 5,074,000
• Market Cap: $2.65 million
• Optionable: Not Optionable
• Beta: -0.11